Abstract: The present invention relates to a composition comprising a first salt, which contains a first anionic pesticide (A1) and a cationic polyamine (B), and a second salt, which contains a second anionic pesticide (A2) and a cationic polyamine (B), wherein both salts contain the same cationic polyamine (B), and wherein the cationic polyamine comprises at least two amino groups. The disclosure further relates to methods for preparing the composition, methods for combatting harmful insects and/or phytopathogenic fungi using the composition, methods for controlling undesired vegetation using the composition, and seeds including the composition.

Abstract: The disclosure relates to adjuvant compositions and related methods for reducing herbicide volatility and/or enhancing herbicide activity. The adjuvant- and herbicide-containing compositions are generally aqueous and include a volatile growth regulator herbicide, an aminopolycarboxylate salt water conditioner, and (optionally) a glyphosate herbicide. The compositions generally have a mildly acidic to mildly basic pH value. When the compositions are applied to a target area to control a target plant in the area with the herbicide, the aminopolycarboxylate salt water conditioner can both potentiate the herbicide as well as reduce volatile transport of the herbicide, thus reducing damage to other (non-target) sensitive plants, whether inside or outside of the target area of application.

Abstract: A process for the preparation of solid amine salts of aromatic substituted carboxylic acid herbicides by reaction of the aromatic substituted carboxylic acid herbicide with an amine comprising reacting the aromatic substituted carboxylic acid herbicide in an ether solvent with an amine to form the amine salt and collecting the amine salt of the aromatic substituted carboxylic acid herbicide as a precipitate from the ether solvent reaction mixture wherein the ether is a dialiphatic ether comprising at least one primary aliphatic group.

Abstract: Novel processes for the preparation of a compound of Formula I-2 substantially free of the 5,6-trans isomer: wherein R2, R3 and R4 are as defined in the specification are provided. Novel intermediates for the preparations of isomer free Prostaglandins and derivatives thereof are also provided.

Abstract: A method of reducing the virulence of a bacterium that expresses accessory gene regulator A (AgrA) includes administering to the bacterium an amount of AgrA antagonist effective to inhibit the synthesis of one or more virulence factors by the bacterium.

Abstract: A method is disclosed for the Agrobacterium-mediated germline transformation of soybean, comprising infecting split soybean seeds, with a portion of the embryonic axis, with Agrobacterium tumefaciens containing a transgene. The method can further comprise regenerating the explants produced from the transformation of the split soybean seeds comprising a portion of embryonic axis in vitro on selection medium.

Abstract: A compound of formula (I) wherein Rf is —CF3, —C2F5, or —CF2CFXCF3; X is —F, or —OC3F7; Y is —H, —Cl, or —Br; R is —OH, —(CH2)nOH, —(OCH2CH2)mOH, —(CH2)n(OCH2CH2)mOH, —O—C(O)—R1, —(CH2)nO—C(O)R1, —(OCH2CH2)mOC(O)—R1, —C(O)NHw(CH2CH2OH)2-w, —C?N, —C?CH, or —C(O)R2; n is 1 to 10; m is 1 to 10; R1 is C1 to C10 alkyl; R2 is —H, C1 to C10 alkyl, —Cl, or —OCH2CH2OH; a is 1 to 5; b is 1 to 5; and w is 0, 1 or 2.

Abstract: The invention relates to substituted phenoxyacetic acids of formula (I), where the variables are as defined in claim 1, as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

Abstract: Soluble granule formulations of amine salts of pyridine containing carboxylic acids with improved handling properties are provided by an improved process in which the pyridine containing carboxylic acid is partially neutralized with an amine.

Abstract: A process for the preparation of solid amine salts of aromatic substituted carboxylic acid herbicides by reaction of the aromatic substituted carboxylic acid herbicide with an amine comprising reacting the aromatic substituted carboxylic acid herbicide in an ether solvent with an amine to form the amine salt and collecting the amine salt of the aromatic substituted carboxylic acid herbicide as a precipitate from the ether solvent reaction mixture wherein the ether is a dialiphatic ether comprising at least one primary aliphatic group.

Abstract: Methods and compositions are disclosed for stimulating weight loss and/or lowering triglyceride levels in an individual mammal in need thereof. In an exemplary method, a pharmaceutical composition comprising a therapeutically effective amount of DITPA, and optionally one or more lipid-reducing agents, is administered to an individual mammal to stimulate weight loss, and/or reduce levels of triglyceride and/or lipoprotein in the mammal.

Abstract: Complexes of herbicidal carboxylic acids and amine-containing polymers or oligomers are provided. These herbicidal complexes are useful for controlling unwanted plant growth. The herbicidal complexes have low solubility in water, low volatility relative to commercial compositions of the corresponding herbicidal carboxylic acids, and offer similar or improved herbicidal performance when compared to existing salts of the herbicidal carboxylic acids.

Abstract: The present invention relates to polymer, homo- or copolymer or oligomer for the photoalignment of liquid crystals comprising a main chain and a side chain, wherein the side chain comprises a difluoromethylene group, compositions thereof, and its use for optical and electro optical devices, especially liquid crystal devices (LCDs).

Abstract: Disclosed are fluorovinyl ether functionalized aromatic diesters and derivatives thereof. The compounds disclosed have utility as functionalized monomers and comonomers in polyesters, polyamides, and the like. It has been found that incorporation of the monomers into polymers provides improved soil resistance to shaped articles produced from the polymers.

Abstract: Disclosed herein are compounds of the formula or salts or bioisosteres thereof. Therapeutic methods, medicaments, and compositions related thereto are also disclosed.

Abstract: The invention encompasses formulations for increased attachment and retention systems of biologically active organic compounds and methods for the preparation and use thereof.

Abstract: Methods and compositions are provided for modulating the activity of human type I taste receptor subunit 3 (hT1R3). Such materials and methods are useful for the screening and preparation of compositions and methods for the treatment of carbohydrate and lipid metabolic diseases and disorders.

Abstract: The invention relates to novel acylpiperazinone compounds, to the preparation of the compounds and intermediates used therein, to the use of the compounds as antibacterial medicaments and pharmaceutical compositions containing the compounds.

Abstract: The present invention provides the use of (?) (3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia.

Abstract: The present invention relates to a salt comprising an anionic pesticide and a cationic polyamine of the formula (A) or (B) as described in the description. The invention further relates to an agrochemical composition comprising said salt. It also relates to a method for preparing said salt comprising combining the pesticide in its neutral form or as salt, and the polyamine in its neutral form or as salt. In addition, the invention relates to a method of combating harmful insects and/or phytopathogenic fungi. It also relates to a method of controlling undesired vegetation. Finally, the invention relates to seed comprising said salt.

Abstract: The present invention is directed to novel macrocyclic compounds of formula (I) and their pharmaceutically acceptable salts, hydrates or solvates: wherein R1, R2, R3, R4, R5, R6 , n1, m, p Z1, Z2, and Z3 are as describe in the specification. The invention also relates to compounds of formula (I) which are antagonists of the motilin receptor and are useful in the treatment of disorders associated with this receptor and with or with motility dysfunction.

Abstract: The present invention concerns substituted 1,3-diphenylpropane derivatives, pharmaceutical compositions comprising them and the therapeutic uses thereof, particularly in the field of human and animal health.

Abstract: The present application relates to novel difluorophenol derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prevention of cardiovascular disorders.

Abstract: A diamine compound of formula (I) is proposed as well as polymers, copolymers, polyamic acids, polyamic acid esters, or polyimides based on such compound.

Abstract: The present invention provides a method and a composition for restoring pollen fertility by suppressing formation insufficiency in a pollen formation process due to a high-temperature or low-temperature stress. The present invention provides a fertility restorative agent comprising an auxin as an active ingredient, and a method for restoring the fertility of a plants of the family Poaceae, comprising spreading an auxin. Moreover, the present invention provides a fertility restorative agent containing as an active ingredient a substance which inhibits auxin action, and a method for restoring the fertility of rice plant, including spreading a substance which inhibits auxin action.

Abstract: The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

Abstract: This invention is directed to the crystalline potassium salt of a lipoxin A4 analog of Formula (I): processes for preparing the crystalline potassium salts, methods for using them to treat disease-states characterized by inflammation, and pharmaceutical compositions comprising such crystalline potassium salts.

Abstract: A process for preparing monocarboxylic perfluoropolyethers of formula: A-O—(RF)z—(CFY)t—C(O)OX (I) wherein: X is H, C1-C10 alkyl, or an aryl group; Y=F, CF3; t=1, 2 or 3; A is a C1-C4 perfluoroalkyl end group; z=0 or 1; RF is a perfluorooxyalkylene chain; having a number average molecular weight in the range 180-8,000; comprising the following steps: a) one or more distillations of perfluoropolyethers (PFPE) of formula T-O—(RF)z-T? (II) wherein: z and RF are as above defined; T, T?, equal to or different from each other, are selected from acyl fluoride or carbonyl-containing functional end groups and non functional end groups to obtain one PFPE fraction of formula (II) wherein the difference between the minimum and the maximum molecular weight of the components is lower than or equal to 600; b) partial fluorination of the fraction obtained in a); c) esterification c1) and/or hydrolysis c2) of the mixture obtained in b); d) distillation of the product obtained in c2) or in c1).

Abstract: An agent for regulating 14273 receptor function, which is useful as a preventing or treating drug for diabetes mellitus, hyperlipidemia or the like, is provided. An agent for regulating 14273 receptor function comprising a compound containing an aromatic ring and a group capable of releasing a cation.

Abstract: The invention relates to substituted phenoxyacetic acids (I) as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

Abstract: The present invention provides a new pharmaceutical application of a 15,15-difluoroprostaglandin F2? derivative. As a result of intensive studies in order to find a new pharmaceutical application of a 15,15-difluoroprostaglandin F2? derivative, it was found that, in a European Phase III clinical trial for tafluprost, one of the 15,15-difluoroprostaglandin F2? derivatives, with patients with open-angle glaucoma or ocular hypertension, tafluprost has actions of growing eyelashes, making eyelashes thicker, and changing the color thereof, that is, has an effect of promoting the growth of hair (eyelashes). Therefore, a 15,15-difluoroprostaglandin F2? derivative is useful as a hair growth promoting agent, and is expected to be useful as an active ingredient of a preventive or therapeutic agent for a disease associated with hair such as alopecia and a hair care product or a hair cosmetic product for regrowing hair, growing hair, increasing hair density, nourishing hair, or the like.

Abstract: The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

Abstract: This invention is directed to the crystalline potassium salt of a lipoxin A4 analog of Formula (I): processes for preparing the crystalline potassium salts, methods for using them to treat disease-states characterized by inflammation, and pharmaceutical compositions comprising such crystalline potassium salts.

Abstract: New fluorinated ethers of aromatic acids and diesters are disclosed. These compositions can be applied to, e.g., fibers, yarns, carpets, garments, films, molded parts, paper and cardboard, stone, and tile to impart soil, water and oil resistance. By incorporating the fluorinated ethers of aromatic acids, or diesters thereof, into polymer backbones, more lasting soil, water and oil resistance, as well as improved flame retardance, can be achieved.

Abstract: The present invention concerns substituted 1,3-diphenylpropane derivatives, pharmaceutical compositions comprising them and the therapeutic uses thereof, particularly in the field of human and animal health.

Abstract: 3-(2,4-Bis(trifluoromethyl)benzyloxy)phenylacetic acid, 4-(2,6-Dimethylbenzyloxy)-phenylacetic acid, and their pharmaceutically acceptable salts are useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis.

Abstract: The invention relates to compounds of the formula I: and to the pharmaceutically acceptable salts thereof, to processes for the preparation of them and to pharmaceutical compositions comprising them, which are useful especially for the treatment and prevention of dyslipidaemia, atherosclerosis and diabetes.

Abstract: The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.

Abstract: The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.

Abstract: The invention relates to substituted 1,3-diphenylprop-2-en-1-one derivative compounds, pharmaceutical and/or cosmetic compositions containing same, and the applications thereof in therapeutics and cosmetics. The invention also relates to a method for preparing said derivatives.

Abstract: The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

Abstract: Administration of a therapeutically effective amount of 3,5-diiodothyropropionic acid stimulates weight loss in patients, lowers triglyceride levels and reduces risk of death or progression of coronary heart disease in patients with metabolic syndrome.

Abstract: Novel compounds of the general formula (I), the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are activators of PPAR? and should be useful for treating conditions mediated by the same.

Abstract: Compounds of the formula (I): in which R, R1, R2 and R3 are as defined in the description, to their use for the treatment of dyslipidaemia, atherosclerosis and diabetes, to pharmaceutical compositions comprising them and to the processes for the preparation of these compounds.

Abstract: The present invention provides compounds useful, for example, for modulating insulin levels in a subject, having the general formula I: wherein Q is an optionally substituted phenyl; L is a bond or O; P is a benzene or an optionally substituted thiazole ring; and R1 has the values provided herein. The present invention also provides compositions, uses, and methods for use of the compounds, for instance, for treatment of type II diabetes.

Abstract: A process for preparing a quaternary ammonium salt of a fibric acid, represented by the following reaction scheme: is carried out in a single operation starting from a phenol of formula (I), an ?-halogenated ester of formula (II) and a quaternary ammonium hydroxide of formula (III). This process makes it possible economically to prepare a choline salt of fenofibric acid in high purity that can be used directly as the active substance in a pharmaceutical composition intended for human consumption.

Abstract: The present invention provides a methods and compounds for producing an enantiomerically enriched ?-(phenoxy)phenylacetic acid compound of the formula: from a mixture of its enantiomers, where R1 is alkyl or haloalkyl and X is halide.

Abstract: Disclosed herein are compounds of the formula or salts or bioisosteres thereof. Therapeutic methods, medicaments, and compositions related thereto are also disclosed.

Abstract: Provided herein are assays for detecting enzyme activity using Raman Spectroscopy.

Abstract: An agent for regulating 14273 receptor function, which is useful as a preventing or treating drug for diabetes mellitus, hyperlipidemia or the like, is provided. An agent for regulating 14273 receptor function comprising a compound containing an aromatic ring and a group capable of releasing a cation.